Strategies for ocular siRNA delivery: Potential and limitations of non-viral nanocarriers

Journal of Biological Engineering

Volumn 6, Issue , 2012, Pages

  Thakur, Ajit ^a   Fitzpatrick, Scott ^b   Zaman, Abeyat ^c   Kugathasan, Kapilan ^d   Muirhead, Ben ^b   Hortelano, Gonzalo ^b   Sheardown, Heather ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Biomaterials; Drug delivery; Endosomal escape; Nanocarriers; Ocular siRNA delivery; RNAi; siRNA

Indexed keywords

DENDRIMER; LIPID NANOCARRIER; NANOCARRIER; PROTEIN NANOCARRIER; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; BLURRED VISION; CATARACT; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; ENDOPHTHALMITIS; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; MICELLE; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA HEMORRHAGE; RETINA TEAR; RNA INTERFERENCE; VITREOUS FLOATERS; VITREOUS HEMORRHAGE;

EID: 84861993060     PISSN: None     EISSN: 17541611     Source Type: Journal    
DOI: 10.1186/1754-1611-6-7     Document Type: Article

References (104)

1. Duvvuri S, Majumdar S, Mitra AK. Drug delivery to the retina: challenges and opportunities. Expert Opin Biol Ther 2003, 3:45-56. 10.1517/14712598.3.1.45, 12718730.
2. Del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug DiscovToday 2008, 13:135-143.
3. Novack GD. Ophthalmic drug delivery: development and regulatory considerations. ClinPharmacolTher 2009, 85:539-543.
4. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 2006, 58:1131-1135. 10.1016/j.addr.2006.07.027, 17097758.
5. Edelhauser HF, Rowe-Rendleman CL, Robinson MR, Dawson DG, Chader GJ, Grossniklaus HE, Rittenhouse KD, Wilson CG, Weber DA, Kuppermann BD, et al. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci 2010, 51:5403-5420. 10.1167/iovs.10-5392, 3061492, 20980702.
6. Kang Derwent JJ, Mieler WF. Thermoresponsive hydrogels as a new ocular drug delivery platform to the posterior segment of the eye. TransAmOphthalmolSoc 2008, 106:206-213.
7. Lee SS, Robinson MR. Novel drug delivery systems for retinal diseases. A review. Ophthalmic Res 2009, 41:124-135.
8. Kuno N, Fujii S. Biodegradable intraocular therapies for retinal disorders: progress to date. Drugs Aging 2010, 27:117-134. 10.2165/11530970-000000000-00000, 20104938.
9. Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, Tolentino M, Gupta A, Duarte L, Madreperla S, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011, 118:626-635. e622, 10.1016/j.ophtha.2010.12.028, 21459216.
10. London NJ, Chiang A, Haller JA. The dexamethasone drug delivery system: indications and evidence. Adv Ther 2011, 28:351-366. 10.1007/s12325-011-0019-z, 21494891.
11. Eljarrat-Binstock E. Pe'er J, Domb AJ: New techniques for drug delivery to the posterior eye segment. Pharm Res 2010, 27:530-543. 10.1007/s11095-009-0042-9, 20155388.
12. Reischl D, Zimmer A. Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomedicine: Nanotechnology, Biology and Medicine 2009, 5:8-20.
13. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans. Nature 1998, 391:806-811. 10.1038/35888, 9486653.
14. Elbashir S, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498. 10.1038/35078107, 11373684.
15. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nature Rev Drug Discov 2007, 6:443-453.
16. Ahmed SU, Milner J. Basal Cancer Cell Survival Involves JNK2 Suppression of a Novel JNK1/c-Jun/Bcl-3 Apoptotic Network. PLoS One 2009, 4:e7305. 10.1371/journal.pone.0007305, 2752166, 19806201.
17. Watts JK, Deleavey GF, Damha MJ. Chemically modified siRNA: tools and applications. Drug Discovery Today 2008, 13:842-855. 10.1016/j.drudis.2008.05.007, 18614389.
18. Whitehead K, Langer R, Anderson D. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009, 8:129-138. 10.1038/nrd2742, 19180106.
19. Kennedy S, Wang D, Ruvkun G. A conserved siRNA-degrading RNase negatively regulates RNA interference in C. elegans. Nature 2004, 427:645-649.
20. Pirollo K, Chang E. Targeted delivery of small interfering RNA: approaching effective cancer therapies. Cancer Res 2008, 68:1247-1250. 10.1158/0008-5472.CAN-07-5810, 18316585.
21. Mohan R, Tovey J, Sharma A, Tandon A. Gene therapy in the Cornea: 2005-present. Prog Retin Eye Res 2012, 31:43-64. 10.1016/j.preteyeres.2011.09.001, 21967960.
22. Couto L, High K. Viral vector-mediated RNA interference. Curr Opin Pharmacol 2010, 10:534-542. 10.1016/j.coph.2010.06.007, 20620113.
23. Wu L, Lam S, Cao H, Guan R, Hu J. Subretinal gene delivery using helper-dependent adenoviral vectors. Cell Biosci 2011, 1:15. 10.1186/2045-3701-1-15, 3125205, 21711866.
24. Höbel S, Koburger I, John M, Czubayko F, Hadwiger P, Vornlocher H, Aigner A. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab. J Gene Med 2010, 12:287-300.
25. Hirano Y, Sakurai E, Matsubara A, Ogura Y. Suppression of ICAM-1 in retinal and choroidal endothelial cells by plasmid small-interfering RNAs in vivo. Invest Ophthalmol Vis Sci 2010, 51:508-515. 10.1167/iovs.09-3457, 19578010.
26. Conley S, Naash M. Nanoparticles for retinal gene therapy. Prog Retin Eye Res 2010, 29:376-397. 10.1016/j.preteyeres.2010.04.004, 2907107, 20452457.
27. Khar R, Jain G, Warsi M, Mallick N, Akhter S, Pathan S, Ahmad F. Nano-vectors for the Ocular Delivery of Nucleic Acid-based Therapeutics. Indian J Pharm Sci 2010, 72:675-688. 10.4103/0250-474X.84575, 3178967, 21969738.
28. Naik R, Mukhopadhyay A, Ganguli M. Gene delivery to the retina: focus on non-viral approaches. Drug Discov Today 2009, 14:306-315. 10.1016/j.drudis.2008.09.012, 18973824.
29. Boussif O. Lezoualc'h F, Zanta M, Mergny M, Scherman D, Demeneix B, Behr J: A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. PNAS 1995, 92:7297-7301. 10.1073/pnas.92.16.7297, 41326, 7638184.
30. Grayson A, Doody A, Putnam D. Biophysical and Structural Characterization of Polyethylenimine-Mediated siRNA Delivery in Vitro. Pharm Res 2006, 23:1868-1876. 10.1007/s11095-006-9009-2, 16845585.
31. Kim B, Tang Q, Biswas P, Xu J, Schiffelers R, Xie F, Ansari A, Scaria P, Woodle M, Lu P, Rouse B. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. Am J Pathol 2004, 165:2177-2185. 10.1016/S0002-9440(10)63267-1, 1618707, 15579459.
32. Günther M, Lipka J, Malek A, Gutsch D, Kreyling W, Aigner A. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. Eur J Pharm Biopharm 2011, 77:438-449. 10.1016/j.ejpb.2010.11.007, 21093588.
33. Duan Y, Guan X, Ge J, Quan D, Zhuo Y, Ye H, Shao T. Cationic nano-copolymers mediated IKKbeta targeting siRNA inhibit the proliferation of human Tenon's capsule fibroblasts in vitro. Mol Vis 2008, 14:2616-2628. 2613073, 19137061.
34. Ye H, Qian Y, Lin M, Duan Y, Sun X, Zhuo Y, Ge J. Cationic nano-copolymers mediated IKKβ targeting siRNA to modulate wound healing in a monkey model of glaucoma filtration surgery. Mol Vis 2010, 16:2502-2510. 2997334, 21139997.
35. Soriano P, Dijkstra J, Legrand A, Spanjer H, Londos-Gagliardi D, Roerdink F, Scherphof G, Nicolau C. Targeted and nontargeted liposomes for in vivo transfer to rat liver cells of a plasmid containing the preproinsulin I gene. PNAS 1983, 80:7128-7131. 10.1073/pnas.80.23.7128, 390006, 6580630.
36. Liu H, Liu Y, Ma Z, Wang J, Zhang Q. A Lipid Nanoparticle System Improves siRNA Efficacy in RPE Cells and a Laser-Induced Murine CNV Model. Invest Ophthalmol Vis Sci 2011, 52:4789-4794. 10.1167/iovs.10-5891, 21519028.
37. Zhang Y, Li H, Sun J, Gao J, Liu W, Li B, Guo Y, Chen J. DC-Chol/DOPE cationic liposomes: a comparative study of the influence factors on plasmid pDNA and siRNA gene delivery. Int J Pharm 2010, 390:198-207. 10.1016/j.ijpharm.2010.01.035, 20116418.
38. Lochmann D, Weyermann J, Georgens C, Prassl R, Zimmer A. Albumin-protamine-oligonucleotide nanoparticles as a new antisense delivery system. Part 1: Physicochemical characterization. Eur J Pharm Biopharm 2005, 59:419-429. 10.1016/j.ejpb.2004.04.001, 15760722.
39. Johnson L, Cashman S, Kumar-Singh R. Cell-penetrating peptide for enhanced delivery of nucleic acids and drugs to ocular tissues including retina and cornea. Mol Ther 2008, 16:107-114. 10.1038/sj.mt.6300324, 17923842.
40. Laufer S, Restle T. Peptide-Mediated Cellular Delivery of Oligonucleotide-Based Therapeutics In Vitro: Quantitative Evaluation of Overall Efficacy Employing Easy to Handle Reporter Systems. Curr Pharm Des 2008, 14:3637-3655. 10.2174/138161208786898806, 2778081, 19075740.
41. Yuan X, Naguib S, Wu Z. Recent advances of siRNA delivery by nanoparticles. Expert Opin Drug Deliv 2011, 8:521-536. 10.1517/17425247.2011.559223, 21413903.
42. Marano R, Wimmer N, Kearns P, Thomas B, Toth I, Brankov M, Rakoczy P. Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide. Exp Eye Res 2004, 79:525-535. 10.1016/j.exer.2004.06.023, 15381036.
43. Marano R, Toth I, Wimmer N, Brankov M, Rakoczy P. Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Ther 2005, 12:1544-1550. 10.1038/sj.gt.3302579, 16034458.
44. Agrawal A, Min D, Singh N, Zhu H, Bhatia S. Functional delivery of siRNA in mice using dendriworms. ACS Nano 2009, 3:2495-2504. 10.1021/nn900201e, 2828182, 19673534.
45. Han L, Zhang A, Wang H, Pu P, Jiang X, Kang C, Chang J. Tat-BMPs-PAMAM conjugates enhance therapeutic effect of small interference RNA on U251 glioma cells in vitro and in vivo. Hum Gene Ther 2010, 21:417-426. 10.1089/hum.2009.087, 19899955.
46. A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) [http://clinicaltrials.gov/ct2/show/NCT00363714].
47. A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration [http://clinicaltrials.gov/ct2/show/NCT00395057].
48. Kaiser P, Symons R, Shah S, Quinlan E, Nguyen Q. RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am J Ophthalmol 2010, 150:33-39. 10.1016/j.ajo.2010.02.006, 20609706.
49. Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (COBALT) [http://clinicaltrials.gov/ct2/show/NCT00499590].
50. Phase II Open Label Multicenter, Prospective, Randomized, Age Related Macular Degeneration, Comparator Controlled Study Evaluating PF-04523655 Versus Ranibizumab In The Treatment Of Subjects With Choroidal Neovascularization (MONET Study) [http://www.clinicaltrials.gov/ct2/show/NCT00713518?term = quark&rank = 7].
51. Prospective, Randomized, Multi-Center, Comparator Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema (DEGAS) [http://www.clinicaltrials.gov/ct2/show/NCT00701181?term = degas&rank = 1].
52. Development pipeline: PF-655 [http://www.quarkpharma.com/qbi-en/products/53/].
53. Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients [http://clinicaltrials.gov/ct2/show/NCT01064505].
54. Tolerance and Effect on Intraocular Pressure After Administration of SYL040012 [http://clinicaltrials.gov/ct2/show/NCT00990743].
55. Tiemann K, Rossi J. RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med 2009, 1:142-151. 10.1002/emmm.200900023, 3378126, 20049714.
56. Morrissey D, Blanchard K, Shaw L, Jensen K, Lockridge J, Dickinson B, McSwiggen J, Vargeese C, Bowman K, Shaffer C, et al. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 2005, 41:1349-1356. 10.1002/hep.20702, 15880588.
57. Pipeline: Development Programs [http://www.alnylam.com/Programs-and-Pipeline/index.php].
58. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005, 23:457-462. 10.1038/nbt1081, 15778705.
59. Prakash T, Allerson C, Dande P, Vickers T, Sioufi N, Jarres R, Baker B, Swayze E, Griffey R, Bhat B. Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J Med Chem 2005, 48:4247-4253. 10.1021/jm050044o, 15974578.
60. Czauderna F, Fechtner M, Dames S, Aygün H, Klippel A, Pronk G, Giese K, Kaufmann J. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 2003, 31:2705-2716. 10.1093/nar/gkg393, 156727, 12771196.
61. Morrissey D, Lockridge J, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, Jadhav V, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nature Biotechnol 2005, 23:1002-1007.
62. Samuel-Abraham S, Leonard J. Staying on message: design principles for controlling nonspecific responses to siRNA. FEBS J 2010, 277:4828-4836. 10.1111/j.1742-4658.2010.07905.x, 21078117.
63. Leuschner P, Ameres S, Kueng S, Martinez J. Cleavage of the siRNA passenger strand during RISC assembly in human cells. EMBO Rep 2006, 7:314-320. 10.1038/sj.embor.7400637, 1456892, 16439995.
64. Hall AH, Wan J, Shaughnessy EE, Ramsay Shaw B, Alexander KA. RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids Res 2004, 32:5991-6000. 10.1093/nar/gkh936, 534620, 15545637.
65. Choung S, Kim Y, Kim S, Park HO, Choi YC. Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem Biophys Res Commun 2006, 342:919-927. 10.1016/j.bbrc.2006.02.049, 16598842.
66. Shim M, Kwon Y. Efficient and targeted delivery of siRNA in vivo. FEBS J 2010, 277:4814-4827. 10.1111/j.1742-4658.2010.07904.x, 21078116.
67. Overhoff M, Sczakiel G. Phosphorothioate-stimulated uptake of short interfering RNA by human cells. EMBO Rep 2005, 6:1176-1181. 10.1038/sj.embor.7400535, 1369202, 16170302.
68. Behlke M. Chemical modification of siRNAs for in vivo use. Oligonucleotides 2008, 18:305-319. 10.1089/oli.2008.0164, 19025401.
69. Jackson A, Burchard J, Leake D, Reynolds A, Schelter J, Guo J, Linsley P. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 2006, 12:1197-1205. 10.1261/rna.30706, 1484422, 16682562.
70. Minks M, West D, Benvin S, Baglioni C. Structural requirements of double-stranded RNA for the activation of 2',5'-oligo(A) polymerase and protein kinase of interferon-treated HeLa cells. J Biol Chem 1979, 254:10180-10183.
71. Marques JT, Williams BRG. Activation of the mammalian immune system by siRNAs. Nat Biotechnol 2005, 23:1399-1405. 10.1038/nbt1161, 16273073.
72. Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ, Albuquerque RJC, Yamasaki S, Itaya M, Pan Y, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008, 452:591-597. 10.1038/nature06765, 2642938, 18368052.
73. Judge A, MacLachlan I. Overcoming the innate immune response to small interfering RNA. Human Gene Therapy 2008, 19:111-124. 10.1089/hum.2007.179, 18230025.
74. Morrissey DV. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nature Biotechnol 2005, 23:1002-1007.
75. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G, Linsley PS. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003, 21:635-637. 10.1038/nbt831, 12754523.
76. Walton S, Wu M, Gredell J, Chan C. Designing highly active siRNAs for therapeutic applications. FEBS J 2010, 277:4806-4813. 10.1111/j.1742-4658.2010.07903.x, 3052974, 21078115.
77. Zuhorn IS, Kalicharan R, Hoekstra D. Lipoplex-mediated transfection of mammalian cells occurs through the cholesterol-dependent clathrin-mediated pathway of endocytosis. J Biol Chem 2002, 277:18021-18028. 10.1074/jbc.M111257200, 11875062.
78. Torchilin V. Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Biopolymers 2008, 90:604-610. 10.1002/bip.20989, 18381624.
79. Petros R, DeSimone J. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010, 9:615-627. 10.1038/nrd2591, 20616808.
80. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin-and caveolae-mediated endocytosis. Biochem J 2004, 377:159-169. 10.1042/BJ20031253, 1223843, 14505488.
81. Fisher D, Ahlemeyer Y, Krieglstein B, Kissel T. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 2003, 24:1121-1131. 10.1016/S0142-9612(02)00445-3, 12527253.
82. Kim BYS, Jiang W, Oreopoulos J, Yip CM, Rutka JT, Chan WCW. Biodegradable Quantum Dot Nanocomposites Enable Live Cell Labeling and Imaging of Cytoplasmic Targets. Nano Letters 2008, 8:3887-3892. 10.1021/nl802311t, 18816147.
83. Rajendran L, Knölker H, Simons K. Subcellular targeting strategies for drug design and delivery. Nat Rev Drug Discov 2010, 9:29-42. 10.1038/nrd2897, 20043027.
84. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, Sugiura Y. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 2001, 276:5836-5840.
85. Ruan G, Agrawal A, Marcus AI, Nie S. Imaging and Tracking of Tat Peptide-Conjugated Quantum Dots in Living Cells: New Insights into Nanoparticle Uptake, Intracellular Transport, and Vesicle Shedding. J Am Chem Soc 2007, 129:14759-14766. 10.1021/ja074936k, 17983227.
86. Derossi D, Joliot A, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 1994, 269:10444-10450.
87. Duan H, Nie S. Cell-penetrating quantum dots based on multivalent and endosome-disrupting surface coatings. J Am Chem Soc 2007, 129:3333-3338. 10.1021/ja068158s, 17319667.
88. Thomas M, Klibanov A. Enhancing polyethylenimine's delivery of plasmid DNA into mammalian cells. PNAS 2002, 99:14640-14645. 10.1073/pnas.192581499, 137472, 12403826.
89. Gusachenko Simonova O, Kravchuk Y, Konevets D, Silnikov V, Vlassov VV, Zenkova MA. Transfection Efficiency of 25-kDa PEICholesterol Conjugates with Different Levels of Modification. J Biomater Sci Polym Ed 2009, 20:1091-1110. 10.1163/156856209X444448, 19454171.
90. Bouxsein N, McAllister C, Ewert K, Samuel C, Safinya C. Structure and gene silencing activities of monovalent and pentavalent cationic lipid vectors complexed with siRNA. Biochemistry 2007, 46:4785-4792. 10.1021/bi062138l, 17391006.
91. Leal C, Bouxsein N, Ewert K, Safinya C. Highly efficient gene silencing activity of siRNA embedded in a nanostructured gyroid cubic lipid matrix. J Am Chem Soc 2010, 132:16841-16847. 10.1021/ja1059763, 2991473, 21028803.
92. Leal C, Ewert K, Shirazi R, Bouxsein N, Safinya C. Nanogyroids incorporating multivalent lipids: enhanced membrane charge density and pore forming ability for gene silencing. Langmuir 2011, 27:7691-7697. 10.1021/la200679x, 3119580, 21612245.
93. Du J, Shi Q, Sun Y, Liu P, Zhu M, Du L, Duan Y. Enhanced delivery of monomethoxypoly(ethylene glycol)-poly(lactic-co-glycolic acid)-poly l-lysine nanoparticles loading platelet-derived growth factor BB small interfering RNA by ultrasound and/or microbubbles to rat retinal pigment epithelium cells. J Gene Med 2011, 13:312-323. 10.1002/jgm.1574, 21674734.
94. Turchinovich A, Zoidl G, Dermietzel R. Non-viral siRNA delivery into the mouse retina in vivo. BMC Ophthalmol 2010, 10:25. 10.1186/1471-2415-10-25, 2959040, 20920307.
95. Aggarwal P, Hall J, McLeland C, Dobrovolskaia A, McNeil S. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 2009, 61:428-437. 10.1016/j.addr.2009.03.009, 19376175.
96. Gref R, Minamitake Y, Peracchia M, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science 1994, 263:1600-1603. 10.1126/science.8128245, 8128245.
97. Wong C, Stylianopoulos T, Cui J, Martin J, Fukumura D. Multistage nanoparticle delivery system for deep penetration into tumor tissue. PNAS 2011, 108:2426-2431. 10.1073/pnas.1018382108, 3038705, 21245339.
98. Gratton S, Ropp P, Pohlhaus P, Luft J, Madden V, Napier M, DeSimone J. The effect of particle design on cellular internalization pathways. PNAS 2008, 105:11613-11618. 10.1073/pnas.0801763105, 2575324, 18697944.
99. Yokoe J, Sakuragi S, Yamamoto K, Teragaki T, Ogawara K, Higaki K, Katayama N, Kai T, Sato M, Kimura T. Albumin-conjugated PEG liposome enhances tumor distribution of liposomal doxorubicin in rats. Int J Pharm 2008, 353:28-34. 10.1016/j.ijpharm.2007.11.008, 18082345.
100. Furumoto K, Yokoe J, Ogawara K, Amano S, Takaguchi M, Higaki K, Kai T, Kimura T. Effect of coupling of albumin onto surface of PEG liposome on its in vivo disposition. Int J Pharm 2007, 329:110-116. 10.1016/j.ijpharm.2006.08.026, 17000067.
101. Davis M, Zuckerman J, Choi C, Seligson D, Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070. 10.1038/nature08956, 2855406, 20305636.
102. Breitbach C, Burke J, Jonker D, Stephenson J, Haas A, Kirn D. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011, 477:99-102. 10.1038/nature10358, 21886163.
103. Hu Y, Atukorale P, Lu J, Moon J, Um S, Cho E, Wang Y, Chen J, Irvine D. Cytosolic delivery mediated via electrostatic surface binding of protein, virus, or siRNA cargos to pH-responsive core-shell gel particles. Biomacromolecules 2009, 10:756-765. 10.1021/bm801199z, 2769516, 19239276.
104. You J, Almeda D, Ye G, Auguste D. Bioresponsive matrices in drug delivery. J Biol Eng 2010, 4.